ZVSA ZyVersa Therapeutics, Inc.
Company Updates ·
ZyVersa said a director has resigned and that it is considering cost reductions, pay cuts for two officers and possible sales of its VAR 200 or IC 100 candidates while it seeks to raise capital.
The Nasdaq Stock Market LLC filed the notice with the SEC on October 6, 2025, citing the rule an exchange uses to remove a security.
Nasdaq told ZyVersa it would announce the delisting on September 18, 2025. The shares have traded on the OTCQB Venture Market since July 28, 2025.
ZyVersa Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing drugs for patients with chronic renal or inflammatory diseases. It holds two globally licensed platforms, both discovered by researchers at the University of Miami Miller School of Medicine. The first is VAR 200, a Cholesterol Efflux Mediator, an injectable form of 2-hydroxypropyl-beta-cyclodextrin for renal diseases, licensed from L&F Research LLC on December 15, 2015. Its lead indication is focal segmental glomerulosclerosis (FSGS), an orphan disease that the text says affects approximately 40,000 people in the United States. The company plans a Phase 2a basket trial in FSGS and Alport syndrome patients in Q2-2026. The second is IC 100, a humanized monoclonal antibody described as an inflammasome ASC inhibitor, in preclinical development for chronic inflammatory diseases. Its lead indication is cardiometabolic conditions associated with obesity. The company plans an IND submission for IC 100 in Q4-2026, followed by a Phase 1 trial in healthy overweight patients with a BMI between 27 – 30. The text notes that chronic kidney disease affects over 750 million people worldwide.
| Product or program | What it is | Stage |
|---|---|---|
| VAR 200 | Injectable cholesterol efflux mediator for renal diseases, lead indication FSGS | Clinical development; Phase 2a basket trial planned for Q2-2026 |
| IC 100 | Humanized monoclonal antibody inhibiting the inflammasome ASC component, for inflammatory conditions | Preclinical development; IND submission planned for Q4-2026 |
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $1.1 million | $1.8 million |
| Net income (loss) | -$25.0 million | -$9.4 million |
| Cash from operations | -$5.1 million | -$7.5 million |
| Cash and equivalents | $101,778 | $1.5 million |
Our latest story on this, dated Oct 6, 2025: "Nasdaq files Form 25 to delist ZyVersa Therapeutics common stock". The story links the filing or release it is based on. Read the story.
ZyVersa Therapeutics, Inc. trades under the ticker ZVSA on OTC.
ZyVersa Therapeutics, Inc. is listed on OTC.
The SEC Central Index Key (CIK) for ZyVersa Therapeutics, Inc. is 1859007. Its filings are on SEC EDGAR.
8,095,921 shares as of 2026-05-11, per the cover page of its 10-Q filed 2026-05-13.
Our directory records ZyVersa Therapeutics, Inc. under United States.
Our directory classifies ZyVersa Therapeutics, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for ZyVersa Therapeutics, Inc. is US98987D3008.
aibio.space lists ZyVersa Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
ZyVersa Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing drugs for patients with chronic renal or inflammatory diseases. It holds two globally licensed platforms, both discovered by researchers at the University of Miami Miller School of Medicine.
VAR 200: Injectable cholesterol efflux mediator for renal diseases, lead indication FSGS Stage: Clinical development; Phase 2a basket trial planned for Q2-2026.
IC 100: Humanized monoclonal antibody inhibiting the inflammasome ASC component, for inflammatory conditions Stage: Preclinical development; IND submission planned for Q4-2026.
ZyVersa Therapeutics, Inc. reported a net loss of $25.0 million for the fiscal year ended Dec 31, 2025, and used $5.1 million of cash in operations, per its annual report to the SEC.
$1.1 million in the fiscal year ended Dec 31, 2025, per its annual report.
Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. Source
Filed to remove its shares from exchange listing. SEC Form 25-NSE. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,9.01). Source
Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02,8.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio